Pandite Arundathy N. sold $210K of STTK
Pandite Arundathy N. (Chief Medical Officer) sold 30,000 shares of Shattuck Labs, Inc. (STTK) at $7.01 ($0.21M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is a single officer open-market sale; it does not include new operational, financial, or regulatory information about STTK.
Market read
Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure limits actionable inference.
What to watch
Insider sales can be driven by tax/vesting schedules; without additional context (e.g., other concurrent insider buys/sales), the signal-to-noise is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Shattuck Labs, Inc. (STTK).
Ticker impact
SEC Form 4 shows CMO Pandite Arundathy N. sold 30,000 STTK shares on 2026-06-30 for ~$210.3K under a 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless accompanied by unusual follow-on selling or other new company news.
The filing is a disclosed open-market sale with an explicit 10b5-1 plan, which typically reduces interpretability as a new negative information signal.
Market effects
Minimal; this is company-specific insider transaction data with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations; traders may ignore it unless there is a pattern of accelerated selling outside plans.
Key entities
- issuerShattuck Labs, Inc.
STTK, the company whose insider transaction is disclosed on Form 4.
- insiderPandite Arundathy N.
Chief Medical Officer who sold 30,000 shares on 2026-06-30 under a 10b5-1 plan.
